Summary
Amgen Inc. reported strong revenue growth in 2020, with total revenues reaching $25.42 billion, a 9% increase driven primarily by the Otezla acquisition and volume growth in key products like Repatha and KYprolis. Despite an overall increase in operating expenses due to Otezla-related costs, the company managed its R&D and SG&A expenses effectively. Amgen also demonstrated its commitment to shareholder returns by increasing its quarterly dividend by 10% and continuing its stock repurchase program. The company is strategically focused on key therapeutic areas including inflammation, oncology/hematology, and cardiovascular disease. Significant pipeline advancements were noted, particularly with the positive results from sotorasib and tezepelumab clinical trials, positioning Amgen for future growth. The company also expanded its global presence through strategic collaborations, such as the investment in BeiGene for the Chinese market, and by establishing a wholly-owned affiliate in Japan. Amgen continues to navigate the challenges of the COVID-19 pandemic, maintaining supply chain stability and adapting its clinical trial operations.
Financial Highlights
55 data points| Revenue | $25.42B |
| Cost of Revenue | $6.16B |
| Gross Profit | $19.27B |
| SG&A Expenses | $5.73B |
| Operating Expenses | $16.29B |
| Operating Income | $9.14B |
| Interest Expense | $1.26B |
| Net Income | $7.26B |
| EPS (Basic) | $12.40 |
| EPS (Diluted) | $12.31 |
| Shares Outstanding (Basic) | 586.00M |
| Shares Outstanding (Diluted) | 590.00M |
Key Highlights
- 1Total revenues increased by 9% to $25.42 billion in 2020, driven by strong product sales growth, including the contribution from the acquired Otezla.
- 2Key products like Repatha and KYprolis showed significant sales growth, indicating strong market performance and pipeline advancement.
- 3Amgen expanded its global reach through a strategic investment in BeiGene to enhance its oncology presence in China and established a wholly-owned affiliate in Japan.
- 4The company advanced its R&D pipeline, with positive clinical trial results for sotorasib (NSCLC) and tezepelumab (severe asthma), signaling potential future blockbusters.
- 5Amgen returned significant capital to shareholders, increasing its quarterly dividend by 10% and repurchasing $3.5 billion of its common stock in 2020.
- 6The company maintained supply chain operations effectively throughout the COVID-19 pandemic, ensuring uninterrupted access to its medicines.
- 7R&D expenses increased slightly to $4.21 billion, supporting the development of its robust pipeline, with increased investment in later-stage clinical programs.